tirzepatide and rheumatoid arthritis Concomitant ixekizumab significantly improved psoriatic disease activity and promoted weight reduction versus ixekizumab alone in adults with PsA and obesity or overweight in the TOGETHER-PsA phase 3b trial. Read GLP-1 drugs could do double

The loophole that keeps Empower operating Compounding pharmacies cannot produce exact copies of commercially available drugs when no shortage exists

The Fate of Foreign Compounds in Biological Systems

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) New England Journal of Medicine 389(24) 2023PMID: 37952131 NEJM 5 U.S

Give your body 30 to 90 days of consistent use to notice shifts in your energy, skin, or overall well-being

Clinical Efficacy Clinical trials demonstrate the potential of retatrutide to induce rapid weight loss

The medication is not approved or intended to be sold, distributed, or reconstituted as a powder for patient use outside of FDA-regulated manufacturing processes